10x Genomics Inc-A 2024年度报告

FORM 10-K__________________________ (Mark One) ☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended December 31, 2024OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934For the transition period fromtoCommission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Registrant as Specified in Its Charter)__________________________ that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.Yes☐No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data Filerequired to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during thepreceding12 months(or for such shorter period that the registrant was required to submit suchfiles).Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use theextended transition period for complying with any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’sassessment of the effectiveness of its internal control over financial reporting under Section 404(b) of theSarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issuedits audit report. Yes☐No☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether thefinancial statements of the registrant included in the filing reflect the correction of an error to previouslyissued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recoveryanalysis of incentive-based compensation received by any of the registrant’s executive officers during therelevant recovery period pursuant to § 240.10D-1(b).☐ Indicateby check mark whether the registrant is a shell company(as defined in Rule 12b-2 ofthe Exchange Act).Yes☐No☐ Aggregate market value of registrant's common stock held by non-affiliates of the registrant, based uponthe closing price of a share of the registrant's common stock on June 30, 2024 (the last business day ofthe registrant's most recently completed second quarter) as reported by Nasdaq on that date was $1.8billion. As of January 31, 2025, the registrant had 108,245,008 shares of Class A common stock, $0.00001 parvalue per share, outstanding and 14,056,833 shares of Class B common stock, $0.00001 par value pershare, outstanding. Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2025 Annual Meeting ofShareholders are incorporated by reference into Part III of this Annual Report on Form 10-K whereindicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commissionwithin 120 days after the end of the registrant’s fiscal year ended December 31, 2024. Table of Contents Table of Contents PART I Item 1.BusinessItem 1A.Risk Factors Item 1B.Unresolved Staff Comments58Item 1C.Cybersecurity58Item 2.Properties59Item 3.Legal Proceedings59Item 4.Mine Safety Disclosures59 PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and IssuerPurchases of Equity Securities60Item 6.[Reserved]61Item 7.Management’s Discussion and Analysis of Financial Condition and Results ofOperations62Item 7A.Quantitative and Qualitative Disclosures About Market Risk74Item 8.Financial Statements and Supplementary Data76Item 9.Changes in and Disagreements With Accountants on Accounting and FinancialDisclosure109Item 9A.Controls and Procedures109Item 9B.Other Information110Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections111PART IIIItem 10.Directors, Executive Officers and Corporate Governance112Item 11.Executive Compensation112Item 12.Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters112Item 13.Certain Relationships and Related Transactions, and Director Independence112Item 14.Principal Accounting Fees and Services112PART IVItem 15.Exhibits, Financial Statement Schedules113Item 16.Form 10-K Summary116Signatures117 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of theSecurities Act of 1933, as amended , and Section 21E of the Securities Exchange A